However, one of the top candidates responsible for PLK-1 re-upregulation in adult leukemia cells upon volasertib treatment was Aurora kinase A. A number of Aurora kinase A inhibitors have already shown convincing results, for example, alisertib, which is currently undergoing clinical evaluation [76]. The gene discussed is AURKA; the disease is leukemia.